

Margaret Moore, MD

Assistant Professor of Pathology
Department of Hematopathology
Virginia Commonwealth University
Email: Margaret.Moore@vcuhealth.org

Education

July 2023 - June 2024	University of Virginia, Charlottesville, Virginia Fellow, Hematopathology
July 2019 - June 2023	University of Virginia, Charlottesville, Virginia Resident, Anatomic and Clinical Pathology
August 2015 - May 2019	University of Virginia, Charlottesville, Virginia Doctor of Medicine
August 2010 - May 2014	University of Richmond, Richmond, Virginia Bachelor of Science in Biochemistry, <i>summa cum laude</i>

Licenses & Certifications

October 2022 - Present: Virginia Medical License

Selected Awards & Honors

June 2023	UVA Resident Citizenship Award
April 2023	UVA Pathology Research Day, Best Clinical Research Poster
May 2019	Dr. James R. Cash Pathology Book Award
January 2017	Alpha Omega Alpha Honor Society

Professional Service (outside)

July 2025 - Present	International Clinical Cytometry Society
April 2023 - Present	Society for Hematopathology
January 2020 - Present	American Society of Clinical Pathology
January 2020 - Present	United States and Canadian Academy of Pathology
July 2019 - Present	Virginia Society for Pathology
July 2019 - Present	College of American Pathologists

Selected Publications

Peer Reviewed

Moore M, Patel P, Tao J. Concurrent involvement of the bone marrow by BRAF V600E-mutant melanoma and hairy cell leukemia. J Hematopathol. 2024;17(4):223-225. doi:10.1007/s12308-024-00609-3

Moore M, Aguilera NS, Obiorah I, et al. Assessment for acceleration and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma using histologic and immunohistochemical features: a case series. J Hematopathol. 2024;17(3):139-147. doi:10.1007/s12308-024-00598-3

Moore M, Chen X, Sadigh S, et al. Evaluating pathologist practices in peripheral blood smear review: A comprehensive practice survey. American Journal of Clinical Pathology. Published online July 22, 2024;aqae091. doi:10.1093/ajcp/aqae091

Moore M, Williams E, Pelkey L, et al. A comparison of WHO-5 and ICC classifications in a series of myeloid neoplasms, considerations for hematopathologists and molecular pathologists. Cancer Genetics. 2024;286-287:25-28. doi:10.1016/j.cancergen.2024.06.003.

Moore M, Courville E, Prakash S, et al. An interactive e-learning module on peripheral blood smear analysis is an effective option for teaching pathology trainees. American Journal of Clinical Pathology. 2023;aqad014.

Moore M, Courville E. Work-up of patients with decreased hemoglobin A2 identified by capillary zone electrophoresis, a North American institutional experience. Laboratory Medicine. 2022;XX:e0–e6.

Moore M, Mills A, Dillon P, et al. Pleomorphic adenoma of the breast: A potential morphologic and molecular pitfall in the era of genomic risk stratification. *Current Problems in Cancer: Case Reports*. 2021;3:100047.

Moore M, Ring KL, Mills AM. TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers. *Modern Pathology*. 2019;32(8):1168-1179.

Dill EA, Gru AA, Atkins KA, Friedman LA, **Moore M**, et al. PD-L1 Expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. *The American Journal of Surgical Pathology*. 2017;41(3):334-342.

Published Educational Materials

Interactive educational modules published electronically by the Society for Hematopathology

Thompson MA, Courville E, **Moore M**. Hodgkin Lymphoma. Society for Hematopathology Interactive Education Modules. 2023. <https://www.society-for-hematopathology.org/web/education-module-view.php?module=34>

Courville E, Siddon A, Balakrishna J, Aguilera N, Arildsen MA, **Moore M**. Practical cases in hemoglobin electrophoresis analysis. Society for Hematopathology Interactive Education Modules. 2022. <https://www.society-for-hematopathology.org/web/education-module-view.php?module=33>

Moore M, Courville E, Qualtieri J, et al. Approach to young blood: Peripheral blood and bone marrow case studies in pediatric patients. Society for Hematopathology Interactive Education Modules. 2022. <https://www.society-for-hematopathology.org/web/education-module-view.php?module=31>

Brown L, Aguilera N, Qualtieri J, Siddon A, **Moore M**, et al. Introduction to bone marrow morphology and evaluation. Society for Hematopathology Interactive Education Modules. 2021. <https://www.society-for-hematopathology.org/web/education-module-view.php?module=29>

Moore M, Courville E. Chronic myeloid leukemia in pediatric patients, a case study. Society for Hematopathology Interactive Education Modules. 2021. <https://www.society-for-hematopathology.org/web/education-module-view.php?module=28>

Abstracts and Presentations

** Indicates meeting presenter*

Bolte F, Natale N, DiBenedetto S, **Moore M**, et al. Spatial transcriptomics of the tumor microenvironment reveals different interferon-related gene signatures in tumor endothelial cells of patients with EGFR and KRAS mutant non-small cell lung cancer. Submitted to American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.

Moore M, Courville E, Craig J, et al. Characteristic blast morphology and immunophenotype assist in identification of trisomy 21 in a setting of limited prenatal care. Accepted to 2025 Society for Hematopathology/European Association for Haematopathology Joint Workshop Meeting.

Moore M, Aguilera N. Peripheral T-cell lymphoma, not otherwise specified, in a robust histiocytic background, an unusual presentation with Pott's-Puffy tumor. Accepted to 2025 Society for Hematopathology/European Association for Haematopathology Joint Workshop Meeting.

***Moore M**. Society for hematopathology education committee results: Pathologist practices in peripheral blood smear review. Society for Hematopathology Program Directors Meeting. USCAP 2024.

Pelkey L, **Moore M**, El Chaer F, et al. A comparison of World Health Organization and International Consensus Classification systems for myeloid neoplasms and implications for pathology reporting. Abstracts and Case studies from the College of American pathologists 2023 annual meeting(Cap23). Archives of Pathology & Laboratory Medicine. 2023;147(9):e2-e154

***Moore M**, Prakash S, Brown L, et al. An interactive E-learning module on peripheral blood smear analysis is an effective option for teaching pathology trainees. USCAP 2023 abstracts education. Laboratory Investigation. 2023;103(3):100086.

***Moore M**, Aguilera N, Obiorah I, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with features of acceleration/transformation is difficult to define by histologic or immunohistochemical criteria. USCAP 2023 abstracts hematopathology. Laboratory Investigation. 2023;103(3):100106.

***Moore M**, Mills AM, Melson J, et al. Examination of PD-L1 and MHC class I expression in non-small cell lung cancer patients receiving immune checkpoint inhibitor therapy. Abstracts from USCAP 2021: Pulmonary, Mediastinal, Pleural, and Peritoneal Pathology (910-952). Modern Pathology. 2021;34(S2):1237-1291.

***Moore M**, Stelow EB. HLA-1 loss is common in non-small cell lung cancer and may contribute to failure of immune checkpoint therapy. Abstracts from USCAP 2020: Pulmonary, Mediastinum, Pleura, and Peritoneum Pathology (1869-1980). Modern Pathology. 2020;33(2):1934-2024.

***Moore M**, Friedman L, Ring K, et al. The targetable immune checkpoint VISTA is highly expressed in a subset of endometrial carcinomas, particularly those exhibiting mismatch repair deficiency and PD-L1 expression. Abstracts from USCAP 2020: Gynecologic and Obstetric Pathology (1047-1234). Modern Pathology. 2020;33(2):1164-1337.

***Moore M**, Shanes E, Dillon P, et al. Pleomorphic adenoma of the breast: a potential morphologic and molecular pitfall. Abstracts and Case Studies from the College of American Pathologists 2019 Annual Meeting (CAP19). Archives of Pathology & Laboratory Medicine. 2019;143(9):e2-e226.

Mcloughlin E, Hanson L, **Moore M**, et al. Clinical characteristics and outcomes in NSCLC patients associated with very high PD-L1 expression. Journal of Thoracic Oncology. 2019;14(10):S659-S660.

Moore M, Hall R, Mcloughlin E, et al. P2.04-75 Overall survival by IDO1 and PD-L1 expression in NSCLC patients receiving an immune checkpoint inhibitor (ICI). Journal of Thoracic Oncology. 2019;14(10):S738.

Melson J, Reed D, Horton BJ, **Moore M**, et al. Immune-related adverse events in advanced NSCLC treated with immunotherapy alone or concurrent chemotherapy and immunotherapy. Journal of Clinical Oncology. 2019;37(8_suppl):83-83.

***Moore M**, Ring K, Mills A. The immune checkpoint TIM-3 is highly expressed in a subset of endometrial carcinomas, particularly in the context of MLH1-hypermethylation. Abstracts from USCAP 2019: Gynecologic and Obstetric Pathology (993-1161). Modern Pathology. 2019;32(2):1-140.

Brown J, Li L, **Moore M**, et al. Impact of urban or rural residence on overall survival for patients with metastatic non-squamous NSCLC. Journal of Thoracic Oncology. 2018;13(10):S870.

Geisler D, Friedman LA, **Moore M**, et al. PD-L1 expression in villitis of unknown etiology. Abstracts from USCAP 2017: Pediatric Pathology. Modern Pathology. 2017;30(2):464-471.